MAOB and Parkinson disease: However, these properties were not confirmed and in 2006 the American Association of Neurology (Suchowersky et al., 2006a), and in 2010 Romanian guidelines (Neurology, 2025b), recommend starting therapy with dopamine agonists or other dopaminergic therapies (MAO-B inhibitors or levodopa) in the early stages of PD if the motor symptoms do not impact patients’ quality of life (QoL).